The estimated Net Worth of Bosun Hau is at least $124 Tysiąc dollars as of 6 June 2018. Mr. Hau owns over 2,898 units of Exicure Inc stock worth over $15,562 and over the last 7 years he sold XCUR stock worth over $0. In addition, he makes $107,970 as Independent Director at Exicure Inc.
Bosun has made over 2 trades of the Exicure Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 2,898 units of XCUR stock worth $101,256 on 6 June 2018.
The largest trade he's ever made was buying 7,142 units of Exicure Inc stock on 4 June 2018 worth over $208,475. On average, Bosun trades about 1,004 units every 0 days since 2018. As of 6 June 2018 he still owns at least 10,040 units of Exicure Inc stock.
You can see the complete history of Mr. Hau stock trades at the bottom of the page.
Bosun S. Hau serves as Independent Director of the Company. He has served as a member of our Board of Directors since August 2019. Since April 2019, he has served as a Managing Director and Co-Head of Private Equity at Tybourne Capital Management (HK) LTD., a Hong Kong based global public and private equity investment management firm. From October 2015 to April 2019, Mr. Hau served as a Managing Director and Partner at Sailing Capital (HK) LTD., a Hong Kong and Shanghai based global private equity firm. From August 2009 to October 2015, Mr. Hau served as a Partner of MVM Partners LLP, a Boston and London based healthcare investment firm. From 2008 to 2009, Mr. Hau served as a management consultant with McKinsey & Company LP in Southeast Asia and as an early stage biotechnology investor with S.R. One Ltd, GlaxoSmithKline’s corporate venture group. From July 2004 to August 2007, Mr. Hau served as an equity research analyst covering the medical device and pharmaceutical industries for JP Morgan Securities, Inc. and Prudential Securities, Inc. Mr. Hau started his career in sales and marketing at Eli Lilly & Company. Mr. Hau serves on the board of directors of Bicycle Therapeutics plc and is a board overseer of Beth Israel Deaconess Medical Center in Boston, a major teaching hospital of Harvard Medical School. Mr. Hau served as a director of Evolus, Inc., from February 2018 until April 2020. Mr. Hau received a B.S. in Molecular and Cellular Biology, a B.S.H.S. in Physiological Sciences and a B.A. in Psychology from the University of Arizona, an M.Sc. in Biotechnology from Johns Hopkins University and an M.B.A. in Finance and Health Management from the Wharton School at the University of Pennsylvania. Our Board believes that Mr. Hau’s experience in corporate management as well as his experience as an early stage biotechnology investor qualify him to serve on the Board.
As the Independent Director of Exicure Inc, the total compensation of Bosun Hau at Exicure Inc is $107,970. There are 5 executives at Exicure Inc getting paid more, with David Giljohann having the highest compensation of $785,462.
Bosun Hau is 41, he's been the Independent Director of Exicure Inc since 2019. There are 9 older and 2 younger executives at Exicure Inc. The oldest executive at Exicure Inc is David Walt, 67, who is the Independent Director.
Bosun's mailing address filed with the SEC is C/O EXICURE, INC., 2430 N. HALSTED STREET, CHICAGO, IL, 60614.
Over the last 6 years, insiders at Exicure Inc have traded over $4,850,172 worth of Exicure Inc stock and bought 7,217,940 units worth $10,705,021 . The most active insiders traders include Timothy P Walbert, Co., Ltd. Dgp oraz Usa, Inc. Cbi. On average, Exicure Inc executives and independent directors trade stock every 90 days with the average trade being worth of $928,360. The most recent stock trade was executed by Co., Ltd. Dgp on 29 February 2024, trading 3,400,000 units of XCUR stock currently worth $4,488,000.
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Exicure Inc executives and other stock owners filed with the SEC include: